ArticleJournal of translational autoimmunity2026
Long-term natural history of thyroid peroxidase antibodies in a population-based cohort: Findings from 18 years of follow-up in Tehran Thyroid Study (TTS).
Article in Journal of translational autoimmunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Age-dependent association of thyroid peroxidase antibodies with incident cardiovascular disease events: Insights from a longitudinal cohort study.Journal of translational autoimmunity · 2026Article
- Dynamic patterns of thyroid hormones and incident chronic kidney disease: evidence from 18 years of follow-up in the Tehran Thyroid Study.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid peroxidase antibody (TPOAb) is considered a highly sensitive marker of autoimmune thyroid diseases (AITD). Limited longitudinal data exist regarding its long-term natural history in the general population. This study aimed to assess risk factors for TPOAb positivity and its 18-year prevalence, incidence, trajectories, and projected prevalence for the year 2030 in a population-based cohort. Methods: A total of 5,438 adults were recruited at first visit (1999-2002) and followed across four subsequent visits up to 2018 in the iodine-sufficient population-based Tehran Thyroid Study (TTS). The age- and sex-standardized prevalence of TPOAb positivity was calculated, and the projected prevalence in 2030 was estimated using Poisson Generalized Linear Mixed Model (Poisson GLMM). Longitudinal trajectories of TPOAb were identified using latent class growth mixture model (LCGMM). Cox proportional hazards models were used to examine associations between potential risk factors and TPOAb positivity. Results: The prevalence increased progressively from 11.7% at the first visit (1999-2002) to 16.3% at the fifth visit (2015-2018), and is projected to reach 21.04% in 2030. Four distinct TPOAb trajectories were identified: Low-stable (81.4%), Low-increasing (2.9%), High-decreasing (2.4%), and High-stable (13.3%). The overall incidence rate of TPOAb positivity was 5.6 per 1,000 person-years, higher among women and individuals aged <40 years. In multivariable analysis, female sex (Hazard Ratio (HR) = 1.61; 95% CI: 1.15-2.27) and elevated TSH ≥5 mU/L (HR = 2.69; 95% CI: 1.57-4.63) were significant positive predictors of TPOAb positivity, while age between 40 and 60 years was inversely associated with incident TPOAb positivity (HR = 0.71; 95% CI: 0.55-0.90). Conclusions: This is the first and longest study worldwide that demonstrated a persistent rise in TPOAb positivity across five repeated measurements in an iodine-sufficient population, driven by female sex, age <40, and TSH ≥5 mU/L, which is projected to reach 21.04% in 2030. Trajectory patterns of TPOAb showed that the majority of participants had consistently low-stable levels of TPOAb.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.